HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

Pyxis Oncology, Inc.

Pyxis Oncology, Inc.

PYXS

0.00

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ: PYXS) with a Buy and maintains $7 price target.